|

Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion

RECRUITINGN/ASponsored by The University of Hong Kong
Actively Recruiting
PhaseN/A
SponsorThe University of Hong Kong
Started2020-09-01
Est. completion2026-01-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07068399

Summary

This is a randomised controlled trial aimed to demonstrate the effect of cardiac extracorporeal shock wave therapy (CSWT) on the angiogenesis effect of myocardium by determining myocardial perfusion and left ventricular function in patients with coronary artery disease (CAD) when measured by cardiac MRI before and after the treatment.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion criteria:

* Patients with symptoms of coronary artery disease
* Patients without obstructive coronary artery disease
* with LVEF not \< 40%.

Exclusion criteria:

* Age \< 18 years,
* Pregnancy or lactation.
* Contraindication to contrast enhanced stress Cardiac Magnetic Resonance (eg. Estimated GFR \<30ml/min/1.73m2, severe allergy to gadolinium based contrast agent, contraindication to adenosine)
* Life expectancy \<24 months
* Haemodynamically unstable
* Participation in other clinical trial within 6 months of enrollment.
* Recent myocardial infarction within 6 months.
* Unable to consent to or perform components of the study.

Conditions2

Coronary Artery DiseaseHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.